Related Experiment Video

Updated: Jan 7, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung

Lei Wang1, Wenxiu Yao2, Hong Shen3

  • 1aShanghai Pulmonary Hospital, Tongji University of School of Medicine, Shanghai, China.

Future Oncology (London, England)
|December 29, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
HARMONi-2IvonescimabPD-L1Squamousclinical trialnon-small cell lung cancernon-squamousplain language summary

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

Related Experiment Videos

Last Updated: Jan 7, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

Articles linked to this work by shared authors, journal, and citation graph.

Call to Improve Coding of Cancer-Associated Cachexia.

JCO oncology practice·2025

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Journal for immunotherapy of cancer·2024

Machine learning identifies immune-based biomarkers that predict efficacy of anti-angiogenesis-based therapies in advanced lung cancer.

International immunopharmacology·2024

Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial.

Lung cancer (Amsterdam, Netherlands)·2024

Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.

JAMA oncology·2024

Multi-omics with dynamic network biomarker algorithm prefigures organ-specific metastasis of lung adenocarcinoma.

Nature communications·2024

Durvalumab plus etoposide-carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E).

Future oncology (London, England)·2026

Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

Future oncology (London, England)·2026

Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.

Future oncology (London, England)·2026

First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis.

Future oncology (London, England)·2026

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

Future oncology (London, England)·2026

Interleukin-6 as a prognostic biomarker in repatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.

Future oncology (London, England)·2026

Exome-wide analysis of rare deleterious variants in 3,569 sarcoma cases and 21,788 controls from multiple international data sources reveals no novel susceptibility genes.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Choosing Wisely in Rural America: Surgical Management of the Axilla in Elderly Patients with Clinically Node-negative, Hormone Receptor-positive Invasive Breast Cancer.

Annals of surgical oncology·2026

Specialized cancer care for medullary thyroid cancer: A Surveillance, Epidemiology, and End Results-Medicare study of Traditional Fee-For-Service and Medicare Advantage beneficiaries.

Surgery·2026

Adrenal Collision Tumors: A Practical Application of the Existing Evidence.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Survival impact of involvement of lymph node stations 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary cancers (PANODE): prospective multicentre study.

BJS open·2026

Correction: Eshaq et al. Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance. Cancers 2024, 16, 2754.

Cancers·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us